Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ahead in the indication.

AbbVie stakes $335M on a startup’s RNAi drugs

Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial

March 12, 2026

NEMA, stakeholders review 2025 disasters, boost preparedness in Kaduna – EnviroNews

March 12, 2026

Source link

Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint

Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial

NEMA, stakeholders review 2025 disasters, boost preparedness in Kaduna – EnviroNews

Peace, Security, and Governance: Breaking the Cycles of Instability in Africa

All of Our Hopes and Fears for Tech in 2025

All of Our Hopes and Fears for Tech in 2025

Leave a Reply Cancel reply

RECOMMENDED NEWS

AU, ECOWAS, and EU rally behind Nigeria amid U.S. threats of military action

Digg’s founders explain how they’re building a site for humans in the AI era

RDI, Foodjustice train govt officials on planetary health diet – EnviroNews

Tesla May Be in a Sales Slump, but EVs Are Doing OK Overall

POPULAR NEWS

Mahama attends Liberia’s 178th independence anniversary

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint

Related posts

Peace, Security, and Governance: Breaking the Cycles of Instability in Africa

All of Our Hopes and Fears for Tech in 2025

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS